Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Andrea Carolina Machado Sulbarán"'
Autor:
José Javier Morales-Núñez, José Francisco Muñoz-Valle, Carlos Meza-López, Lin-Fa Wang, Andrea Carolina Machado Sulbarán, Paola Carolina Torres-Hernández, Martín Bedolla-Barajas, Brenda De la O-Gómez, Paulina Balcázar-Félix, Jorge Hernández-Bello
Publikováno v:
Vaccines, Vol 9, Iss 7, p 742 (2021)
The main expected result of a vaccine against viruses is the ability to produce neutralizing antibodies. Currently, several vaccines against SARS-CoV-2 are being applied to prevent mortal complications, being Pfizer-BioNTech (BNT162b2) one of the fir
Externí odkaz:
https://doaj.org/article/9a7a8959a26a43a6b9770e5f6e4f8829
Autor:
José Javier Morales-Núñez, José Francisco Muñoz-Valle, Andrea Carolina Machado-Sulbarán, Saúl Alberto Díaz-Pérez, Paola Carolina Torres-Hernández, Beatriz Verónica Panduro-Espinoza, Jonathan Adrián Gallegos-Díaz de Leon, Carlos David Munguía-Ramirez, Jorge Hernández-Bello
Publikováno v:
Immunology letters.
Neutralizing antibodies (NAbs) can be indicators of collective immunity, vaccine efficacy, and the longevity of the humoral response. This study aimed to compare reactogenicity and NAbs generated by three different COVID-19 vaccine platforms in indiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d556f8b5b2415243cab867e01beff674
https://pubmed.ncbi.nlm.nih.gov/36279685
https://pubmed.ncbi.nlm.nih.gov/36279685
Autor:
Jorge Hernández-Bello, Carlos Meza-López, Paola Carolina Torres-Hernández, Brenda De la O-Gómez, Martín Bedolla-Barajas, José Javier Morales-Núñez, José Francisco Muñoz-Valle, Lin-Fa Wang, Andrea Carolina Machado Sulbarán, Paulina Balcázar-Félix
Publikováno v:
Vaccines
Volume 9
Issue 7
Vaccines, Vol 9, Iss 742, p 742 (2021)
Volume 9
Issue 7
Vaccines, Vol 9, Iss 742, p 742 (2021)
The main expected result of a vaccine against viruses is the ability to produce neutralizing antibodies. Currently, several vaccines against SARS-CoV-2 are being applied to prevent mortal complications, being Pfizer-BioNTech (BNT162b2) one of the fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f5fece3064d6436f9e7a7e883fa8f60
http://europepmc.org/articles/PMC8310237
http://europepmc.org/articles/PMC8310237
Autor:
Jorge Hernández-Bello, José Javier Morales-Núñez, Andrea Carolina Machado-Sulbarán, Saúl Alberto Díaz-Pérez, Paola Carolina Torres-Hernández, Paulina Balcázar-Félix, Jesús Alberto Gutiérrez-Brito, José Alvaro Lomelí-Nieto, José Francisco Muñoz-Valle
Publikováno v:
Vaccines, Vol 9, Iss 9, p 1047 (2021)
This is the first study outside of clinical trials (phase I–III) evaluating the ability of the Ad5-nCoV vaccine to generate neutralizing antibodies and the factors associated with optimal or suboptimal response. In a longitudinal assay, 346 people
Externí odkaz:
https://doaj.org/article/98fbb9a0f1594a2f918dbadd1a20588c